Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 9/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2646859 | 0.80 | L3MBTL1 (0.54) | PIN1SMN1; SMN2MAPTPOLBHSPB1 | |
| SCHEMBL2645951 | 0.79 | PIN1 (0.47) | PIN1SLC22A12MAPTPOLBGAA | |
| SCHEMBL5943918 | 0.78 | MEN1 (0.47) | SMN1; SMN2MAPTHSPB1 | |
| SCHEMBL27546530 | 0.78 | SLC22A12 (0.45) | SLC22A12FFAR4MAPTPOLBGAA | |
| SCHEMBL2644512 | 0.76 | LPAR1 (0.40) | PIN1SLC22A12MAPT | |
| SCHEMBL2646298 | 0.73 | LMNA (0.38) | PIN1MAPTPOLB | |
| SCHEMBL9132057 | 0.73 | HPGD (0.58) | PIN1SMN1; SMN2POLBGAAHSPB1 | |
| SCHEMBL16052765 | 0.73 | HTT (0.50) | SMN1; SMN2MAPTPOLB | |
| SCHEMBL9131619 | 0.70 | GAA (0.53) | SMN1; SMN2MAPTPOLBGAAMAP4K4 | |
| SCHEMBL7054403 | 0.70 | GAA (0.64) | PIN1SLC22A12SMN1; SMN2POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1702919-B1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | MSD KK (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-7728025-B2 | 2-heteroaryl-substituted benzimidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1702919-A1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | GCK, GCKR, HK1 | PIN1 4516/4885SLC22A12 856/4885FFAR4 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.